Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Evaluating the clinical impact of point-of-care HIV viral load testing in India

EF 2017-18

Résumé
Viral load (VL) monitoring for patients with HIV/AIDS is necessary to assess treatment efficacy and confirm suspected treatment failure. Yet in 2015, fewer than 30% of the 15.8 million people accessing antiretroviral therapy had ever had a VL test; this is because routine VL testing is not available in most high-burden HIV countries. When VL testing is available, it is performed in large batches using expensive, infrastructure demanding equipment that prohibit its use at the point-of-care. Delay in receipt of results translates to delayed clinical decision-making, which may lead to worsened clinical outcomes. The Xpert HIV-1 VL assay is a newly developed, automated and rapid test that can be performed easily at the point-of-care. A study I published last year in Lancet Global Health showed that Xpert HIV-1 VL correlates extremely well with a current gold standard assay. However, there is currently no published data on the clinical impact of implementing Xpert HIV-1 Viral Load at the point-of-care. The objective of my current project is to assess the impact of this same-day VL test in a primary healthcare facility in Manipal, India. We hypothesize that the implementation of point-of-care same-day VL testing will decrease the turn-around-time for VL tests, reduce delays in initiation of second-line treatment regimens, and increase the proportion of patients receiving enhanced adherence counselling. Delayed switching to second-line drug regimens among patients with treatment failure contributes significantly to HIV/AIDS-related mortality. Access to point-of-care VL testing may reduce this delay thereby improving clinical outcomes. The knowledge gained from this study will inform national policy on VL testing for HIV-positive patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
386624
Name
Nash Madlen J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the clinical impact of point-of-care HIV viral load testing in India
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aids; Art; Hiv; Point-Of-Care; Viral Load
Abstract
Viral load (VL) monitoring for patients with HIV/AIDS is necessary to assess treatment efficacy and confirm suspected treatment failure. Yet in 2015, fewer than 30% of the 15.8 million people accessing antiretroviral therapy had ever had a VL test; this is because routine VL testing is not available in most high-burden HIV countries. When VL testing is available, it is performed in large batches using expensive, infrastructure demanding equipment that prohibit its use at the point-of-care. Delay in receipt of results translates to delayed clinical decision-making, which may lead to worsened clinical outcomes. The Xpert HIV-1 VL assay is a newly developed, automated and rapid test that can be performed easily at the point-of-care. A study I published last year in Lancet Global Health showed that Xpert HIV-1 VL correlates extremely well with a current gold standard assay. However, there is currently no published data on the clinical impact of implementing Xpert HIV-1 Viral Load at the point-of-care. The objective of my current project is to assess the impact of this same-day VL test in a primary healthcare facility in Manipal, India. We hypothesize that the implementation of point-of-care same-day VL testing will decrease the turn-around-time for VL tests, reduce delays in initiation of second-line treatment regimens, and increase the proportion of patients receiving enhanced adherence counselling. Delayed switching to second-line drug regimens among patients with treatment failure contributes significantly to HIV/AIDS-related mortality. Access to point-of-care VL testing may reduce this delay thereby improving clinical outcomes. The knowledge gained from this study will inform national policy on VL testing for HIV-positive patients.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nash, Madlen J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~